NCT04686643View on ClinicalTrials.gov

Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension

PHASE3UnknownINTERVENTIONAL
Enrollment

306

Participants

Timeline

Start Date

February 1, 2021

Primary Completion Date

February 1, 2022

Study Completion Date

May 1, 2022

Conditions
Hypertension
Interventions
DRUG

AGSAVI

S-amlodipine, Valsartan, Indapamide

DRUG

AGLS

S-amlodipine, Valsartan

Sponsors
All Listed Sponsors
lead

Ahn-Gook Pharmaceuticals Co.,Ltd

INDUSTRY

NCT04686643 - Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension | Biotech Hunter | Biotech Hunter